Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

• Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Card ...